Zelsuvmi™ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals, Inc. is now FDA approved for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. It is the first novel drug approved for the treatment of...
Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB)....
Zoryve (roflumilast) topical foam, 0.3% from Arcutis Biotherapeutics has received FDA approval for the treatment of seborrheic dermatitis in individuals 9 years of age and older. Once-daily, steroid-free Zoryve is the first drug approved for seborrheic dermatitis with...
FDA has approved the expanded label for LEO Pharma’s Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those...
By Joe Gorelick, MSN, FNP-C With 10 JAK inhibitors now approved by the FDA for use in the US across a range of indications, the significance of the boxed warning for JAK inhibitors to include the risk of major adverse events remains unclear. The lack of clarity with...
— UPDATE: NDA Approvals for 2023 now stand at 54, with a fourth dermatologic indication approved! Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6...